A novel cdk9 inhibitor preferentially targets tumor cells and

HIGHLIGHTS

• who: Top from the Cardiff Research Group, Institute of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff, UK have published the paper: A novel Cdk9 inhibitor preferentially targets tumor cells and, in the Journal: (JOURNAL)
• what: The authors provide proof-of-concept that cdk9 plays a key role in tumor cell survival as selective cdk9 inhibition, using an shRNA strategy, triggered CLL cell apoptosis confirming cdk9 as a potential anti-cancer therapeutic target. The authors demonstrate that CDKI-73 induces a rapid loss of MCL1 protein . To the promising potency and selectivity . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.